2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Vaccines, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Bleeding and Clotting, Platelet Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MPN, CML, Clinical Research, Clinical Trials, Study Population, Human, Adult, Animal Model
PAPER

1961 Integrated serum biomarker, single-cell transcriptomic, and mutational analyses support the mechanism of luspatercept (LUSPA) in transfusion-dependent (TD) myelofibrosis (MF) patients (pts) receiving JAK inhibitors (JAKi) in the phase 3 INDEPENDENCE study

Danny V. Jeyaraju, PhD, Manuel Ugidos, PhD2, Keyur Desai3, Alberto Risueño4, Francesco Passamonti, MD5, Haifa Kathrin Al-Ali, MD6, Julie Vienne Buerki7, Fabian Sanabria8, Rajasekhar Suragani, PhD9
1 Bristol Myers Squibb, Princeton, NJ, United States
2 Bristol Myers Squibb, Princeton, NJ, United States
3 Bristol Myers Squibb, Princeton, NJ, United States
4 Bristol Myers Squibb, Princeton, NJ, United States
5 Dipartimento di Oncologia ed Onco-Ematologia, Università degli Studi di Milano, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
6 Universitätsklinikum Halle (Saale), Halle, Germany
7 Bristol Myers Squibb, Boudry, Switzerland
8 Bristol Myers Squibb, Boudry, Switzerland
9 Bristol Myers Squibb, Princeton, NJ, United States

Background: MF is characterized by ineffective erythropoiesis, leading to anemia. LUSPA, an erythroid maturation agent, binds to TGF-β superfamily ligands to suppress SMAD2/3 signaling and enhance early- and late-stage erythroid differentiation. INDEPENDENCE (NCT04717414) is a phase 3, randomized, placebo-controlled study evaluating LUSPA in TD MF pts receiving JAKi. To understand LUSPA’s biology in MF, we integrated serum pharmacodynamics, single-cell RNA-sequencing (scRNA-seq), and mutational profiling.

 

Methods: Serum biomarkers were measured at Day 1 and Day 169 in responders within the biomarker evaluable population. scRNA-seq analysis was performed in peripheral blood mononuclear cells (PBMCs) in a subset of pts at baseline (BL) only or BL and Wk 24. Targeted next-generation sequencing (NGS) was used to assess BL mutational status (74 gene panel). The above analyses were correlated against the primary endpoint of red blood cell (RBC) transfusion independence for ≥12 consecutive wks starting within the first 24 wks (RBC-TI ≥12) or other clinical parameters.

 

Results: Biomarker analyses confirmed target engagement and preservation of LUSPA’s mechanism of action in responders. Compared to Day 1, at Day 169, LUSPA RBC-TI ≥12 responders demonstrated significant changes in serum biomarkers, including GDF11, a negative regulator of erythropoiesis (decreased from 113 to 92 pg/mL; P=0.015), hemoglobin (increased from 8.58 to 9.40 g/dL; P=0.021), reticulocytes (increased from 65 to 106; P<0.001), and serum EPO levels (increased from 163 to 402 U/L; P=0.010), indicating improved erythropoiesis. Notably, the index of ineffective erythropoiesis (sTfR1/reticulocyte ratio) decreased (459 to 296; P=0.006). Hepcidin, a marker of iron availability, also decreased (233 to 178; P=0.039), suggesting improved iron homeostasis and sustained JAKi effect. None of these changes reached significance in placebo responders (all P≥0.15), confirming a LUSPA-specific signal.

Longitudinal scRNA-seq mirrored observed biological changes in the study. In RBC-TI ≥12 responders, TGF-β/SMAD signaling, MYC, IL6-JAK-STAT, and G2/M checkpoint pathways, along with heme metabolism, declined by Wk 24. In the pool of megakaryocyte-erythroid progenitor (MEP) signature-positive erythroid cells, the MEP erythrocyte fraction that represents the proportion of mature RBCs, decreased from ~75% to 30% in responders and remained stable in non-responders. As scRNA-seq of PBMCs preferentially captures immature erythroid precursors, this reduction is interpreted as a shift toward terminal erythroid differentiation, consistent with the observed reticulocyte dynamics. In contrast, responders showed reduced HSC/MPP (myeloid stem cell/megakaryocyte progenitor), megakaryocyte, and common myeloid progenitor/monocytic fractions, alongside increased CD8+/NK (cytotoxic T cell/natural killer cell) fractions. Interestingly, JAK/STAT and interferon-γ activity remained correlated at both timepoints (R=0.52/0.65, P<0.05), suggesting LUSPA did not disrupt JAKi-mediated JAK-STAT suppression.

BL mutational profiling of 217 pts revealed a diverse and balanced mutational landscape. JAK2 V617F was most prevalent (68% of cases), followed by ASXL1, TET2, CALR, and other genes. A random-effects meta-analysis of RBC-TI ≥12 by mutation showed a favorable effect of LUSPA across mutational subgroups. The pooled risk difference was 0.17 (95% CI, 0.11–0.22) and significant benefit was observed in pts harboring ASXL1, TET2, and HMR mutations. Importantly, independent of treatment (tx) arm and disease risk (MIPSS70+ balanced; P=0.84), pts who subsequently transformed to AML harbored a pre-tx CD34+ hematopoietic progenitor cell state at BL, characterized by enhanced stemness signatures (elevated LSC17 score, notably within MPP-GMP compartment), impaired myeloid maturation programs, and suppressed interferon-γ responses. These features associated with AML transformation were detectable before starting therapy.

 

Conclusion: LUSPA engages GDF11 and activates erythroid maturation in responders without disrupting concomitant JAKi activity. Benefit was observed across mutational backgrounds, and AML transformation appears to be driven by pre-existing disease-intrinsic progenitor biology rather than tx exposure. Collectively, these mechanistic findings provide a coherent biological rationale supporting the clinical benefit of LUSPA in TD MF pts receiving JAKi.

Danny V. Jeyaraju, PhD: Bristol Myers Squibb - Current equity holder in publicly-traded company; Bristol Myers Squibb - Current Employment